Date: 2013-03-05
Type of information: Production agreement
Compound: Active Pharmaceutical Ingredients (API)
Company: DBV Technologies (France) Sanofi (France)
Therapeutic area: Allergic diseases - Immune diseases
Type agreement: production
manufacturing
Action mechanism:
Disease:
Details: DBV Technologies, creator of Viaskin®, a new standard in the treatment of allergies, has announced that it entered into a strategic manufacturing agreement with Sanofi to produce Viaskin’s Active Pharmaceutical Ingredients (API), such as the peanut protein extract. Per the agreement, Sanofi will act as DBV’s Contract Manufacturing Organization (CMO). In this context, Sanofi will scale-up and validate the production process of Viaskin®’s API and full supply at commercial scale.
DBV will benefit from Sanofi’s strong expertise in biologics development and manufacturing in the field of plant extraction and purification of therapeutic proteins to further develop Viaskin®. In addition, the manufacturing site at Aramon (France), which manufactures produces DBV’s APIs, is FDA-approved and has all the necessary capabilities to support the registration of Viaskin® for both the EU and US markets.
Financial terms:
Latest news:
